Finance

Lists
0775:HKG
CK Life Sciences Intl (Holdings) Inc
0,51 HKD
0,00%
(0,00) 1D
16 ოქტ, 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 0775...
Open
0,51 HKD
High
0,52 HKD
Low
0,51 HKD
Mkt. cap
4,90 მლრდ.
Avg. vol.
1,66 მლნ.
Volume
956,00 ათ.
52-wk high
1,02 HKD
52-wk low
0,51 HKD
EPS
-0,01 HKD
Shares outstanding
9,61 მლრდ.
No. of employees
2 ათ.
Open
0,51 HKD
High
0,52 HKD
Low
0,51 HKD
Mkt. cap
4,90 მლრდ.
Avg. vol.
1,66 მლნ.
Volume
956,00 ათ.
52-wk high
1,02 HKD
52-wk low
0,51 HKD
EPS
-0,01 HKD
Shares outstanding
9,61 მლრდ.
No. of employees
2 ათ.
News stories
From web sources and news partners
Profile
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Victor Li Tzar-kuoi, the eldest son of Li Ka-shing, the chairman of Cheung Kong Holdings. It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008. CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector. The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
About CK Life Sciences Intl (Holdings) Inc
CEOინგ ჩო იუ
Employees1,92 ათ.
Founded2000
Headquarters-
Sector-
Websiteck-lifesciences.com
Previous reportsAll values in HKD
Loading Previous Earnings...
Revenue
Net income
All values in HKD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
1,40 მლრდ.
1,40 მლრდ.
1,36 მლრდ.
1,36 მლრდ.
Cost of goods sold
1,01 მლრდ.
1,01 მლრდ.
975,61 მლნ.
975,61 მლნ.
Cost of revenue
1,01 მლრდ.
1,01 მლრდ.
975,61 მლნ.
975,61 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
187,01 მლნ.
187,01 მლნ.
173,47 მლნ.
173,47 მლნ.
Operating expense
440,32 მლნ.
440,32 მლნ.
339,26 მლნ.
339,26 მლნ.
Total operating expenses
1,45 მლრდ.
1,45 მლრდ.
1,31 მლრდ.
1,31 მლრდ.
Operating income
-48,67 მლნ.
-48,67 მლნ.
43,01 მლნ.
43,01 მლნ.
Other non operating income
16,60 მლნ.
16,60 მლნ.
9,78 მლნ.
9,78 მლნ.
EBT including unusual items
58,42 მლნ.
58,42 მლნ.
-9,29 მლნ.
-9,29 მლნ.
EBT excluding unusual items
-87,93 მლნ.
-87,93 მლნ.
-9,29 მლნ.
-9,29 მლნ.
Income tax expense
77,23 მლნ.
77,23 მლნ.
15,02 მლნ.
15,02 მლნ.
Effective tax rate
132,19%
132,19%
-161,72%
-161,72%
Other operating expenses
231,88 მლნ.
231,88 მლნ.
143,42 მლნ.
143,42 მლნ.
Net income
-17,98 მლნ.
-17,98 მლნ.
-14,36 მლნ.
-14,36 მლნ.
Net profit margin
-1,28%
-1,28%
-1,06%
-1,06%
Earnings per share
-
-
-
-
Interest and investment income
5,36 მლნ.
5,36 მლნ.
3,26 მლნ.
3,26 მლნ.
Interest expense
-61,80 მლნ.
-61,80 მლნ.
-65,24 მლნ.
-65,24 მლნ.
Net interest expenses
-56,44 მლნ.
-56,44 მლნ.
-61,97 მლნ.
-61,97 მლნ.
Depreciation and amortization charges
20,80 მლნ.
20,80 მლნ.
21,66 მლნ.
21,66 მლნ.
EBITDA
11,09 მლნ.
11,09 მლნ.
65,38 მლნ.
65,38 მლნ.
Gain or loss from assets sale
-346,73 მლნ.
-346,73 მლნ.
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები